Escitalopram in clinical practice: Results of an open‐label trial in a naturalistic setting

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Depression and Anxiety

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/DA.20051PMID 15786487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer

  2005cited by this paper
• Escitalopram continuation treatment prevents relapse of depressive episodes.

  2004cited by this paper
• Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

  2003cited by this paper
• Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

  2003cited by this paper
• Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care

  2003influential reference
• The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.

  2003cited by this paper
• R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model

  2003cited by this paper
• Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials

  2002influential reference
• Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

  2002influential reference
• Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

  2002influential reference
• Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.

  2001cited by this paper
• Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

  2001cited by this paper
• Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

  2001cited by this paper
• Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

  2000cited by this paper
• The measurement of disability

  1996influential reference
• A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

  1996cited by this paper
• Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse‐Phase Liquid Chromatography

  1995cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper

• Efficacy and Safety of Escitalopram in Alleviating Depression and Anxiety Symptoms in COPD Patients: A Randomized Double-Blind Placebo-Controlled Trial

  2026cites this paper
• Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, Phase 3 clinical trial

  2025influential citation
• The effect of vortioxetine on health-related quality of life in patients with major depressive disorder.

  2015cites this paper
• The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.

  2015cites this paper
• Occupational impact of internet‐delivered cognitive behaviour therapy for depression and anxiety: reanalysis of data from five Australian randomised controlled trials

  2014cites this paper
• Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder.

  2013cites this paper
• Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: an open placebo-controlled study

  2012cites this paper
• Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression

  2012cites this paper
• Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment

  2012cites this paper
• Escitalopram

  2012cites this paper
• Escitalopram and Duloxetine in Major Depressive Disorder

  2012cites this paper
• Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study

  2011cites this paper
• Why do some promising brain-stimulation devices fail the next steps of clinical development?

  2010cites this paper
• Psychopharmacol Brian Leonard and David Taylor major depression translating molecular properties into clinical benefit : reviewing the evidence in − − Review : Escitalopram

  2010influential citation
• Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression

  2010influential citation
• Escitalopram

  2010cites this paper
• Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).

  2010cites this paper
• Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications

  2009cites this paper
• Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients.

  2009cites this paper
• Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report.

  2009cites this paper
• Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients

  2009cites this paper
• Tolerability of Selective Serotonin Reuptake Inhibitors

  2008cites this paper
• Escitalopram in the treatment of obsessive–compulsive disorder

  2008cites this paper
• A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder*

  2008cites this paper
• Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale

  2008influential citation
• A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.

  2008cites this paper
• A surveillance study of escitalopram treatment of depressed patients

  2008cites this paper
• Escitalopram in major depressive disorder: a multicenter, randomized, double‐blind, fixed‐dose, parallel trial in a Chinese population

  2008cites this paper
• Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study.

  2007cites this paper
• Escitalopram in Clinical Practice: Results of an Open-Label Trial in Outpatients with Depression in a Naturalistic Setting in Germany

  2007cites this paper
• Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria

  2007cites this paper
• Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

  2007cites this paper
• Escitalopram in Seasonal Affective Disorder: Results of an Open Trial

  2007cites this paper
• The influence of educational information on depressed outpatients treated with escitalopram: A semi-naturalistic study

  2007influential citation
• A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety

  2007cites this paper
• Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*

  2007cites this paper
• Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life

  2006cites this paper
• Depression and Access to Treatment Among U.S. Hispanics: Review of the Literature and Recommendations for Policy and Research

  2006cites this paper
• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  2006cites this paper
• Current awareness in human psychopharmacology

  2005cites this paper